IL2 and metastatic melanoma: Despite severe toxicity, the potent antitumour activity observed in a subset of patients led to the regulatory approval of a high-dose recombinant IL-2 formulation for cancer immunotherapy of metastatic renal cancer in 1992 and for metastatic melanoma in 1998 (ref. 6).